alzamend.com - ALZN Forward Price-to-Revenue Multiple
The forward P/S history of Alzamend Neuro, Inc. (ALZN) reflects the asset's dynamics amid a severe shortage of Alzheimer's treatments, where captures the current value of the indicator. The business relies on a closed patent perimeter for lithium delivery in psychiatry; however, the lack of profitability and the probability of clinical trial failure create significant financial risks for investors.
Metric breakdowns and analytics for Alzamend Neuro Inc. (ALZN)
- current price and projected stock value:
- issuer market value details:
- business book valuation details:
- debt and solvency information:
Total Debt to Equity Ratio Alzamend Neuro, Inc.|ALZN - Long-Term Debt to Capital|Short-Term Debt to Equity Alzamend Neuro, Inc.|ALZN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Alzamend Neuro|ALZN - Long-Term Debt|Company Current Liabilities Alzamend Neuro|Quick Ratio alzamend.com
- business earnings and investment ratios data:
ALZN - Net Financial Result|Expected Profit Alzamend Neuro, Inc.|ALZN - Price to Earnings Multiple|Forward P/E Multiple Alzamend Neuro, Inc.|ALZN - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Alzamend|ALZN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Alzamend Neuro|ALZN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months alzamend.com|ALZN - Earnings per share growth in current year|Expected earnings per share growth for next year Alzamend Neuro, Inc.
- sales and revenue indicators:
Summary company analysis:ALZN (Alzamend)
When assessing the resilience of Alzamend Neuro, Inc. (ALZN) to market downturns, it is critical to consider the risks of competing with pharma behemoths for leadership in Alzheimer's therapy. By analyzing the projected price-to-sales ratio, an investor determines the market value of a unit of expected revenue, capturing the emotional peaks of the crowd, yet must distinguish short-term speculative volatility from genuine fundamental business development trends.
Competitor analysis
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
